Table of Contents Table of Contents
Previous Page  128 / 398 Next Page
Information
Show Menu
Previous Page 128 / 398 Next Page
Page Background

123

region. The recently developed incident dark-field illumination-

based CytoCam microscope syste

m 1 i

s able to measure the oral

microcirculation at the patient chairside.

Objectives:

The aim of this study was to determine the clin-

ical feasibility of examining and measuring

in vivo

late oral

microcirculatory irradiation injury with the CytoCam handheld

microscope.

Methods:

In a case-control observational study images were

obtained bilaterally from the mandibular gingiva and buccal

mucosa in 14 HN cancer patients and 14 healthy age-matched con-

trols. Tissue functional capillary density (FCD), vessel diameter

(Øbv), and microvascular flow index (MFI) were analysed.

Findings:

Mean gingival and buccal FCD in healthy controls

was 66

±

23 cpll/mm

2

and 19

±

6 cpll/mm

2

, respectively. Buccal

mucosa mean Øbv in healthy controls was 15

±

2 m. A statisti-

cally significant decrease in mean FCD in irradiated mandibular

gingiva was found (

P

< 0.001) and an increased mean Øbv in

irradiated buccal mucosa (

P

< 0.05). No significant differences in

mean buccal FCD was found and MFI was equal in both groups.

Conclusion:

Noninvasive measurements of the oral microcir-

culation using CytoCam microscopy was feasible for detecting

pathophysiological alterations in capillary density and vessel

diameters between irradiated and healthy tissues.

Reference

Hutchings, S., Watts, S., & Kirkman, E. (2016). The Cytocam video micro-

scope. A new method for visualising the microcirculation using Incident

Dark Field technology.

Clin Hemorheol Microcirc

,

62

, 261–271.

http://dx.doi.org/10.1016/j.ijom.2017.02.429

Major maxillofacial surgery in the over 80-year-old patient

— a review of outcomes for East Kent 1997–2016

A. Hills

∗

, J. Patel, H. Dent, J. Mckenzie, N. Goodger,

C. Hendy

East Kent Hospitals University NHS Foundation Trust, United

Kingdom

Background:

Elderly patients are generally frailer and carry a

higher comorbidity burden than the general population, therefore

major surgery holds significant risk of morbidity and mortality for

them.

Objectives:

Review outcomes of major maxillofacial surgeries in

the over 80s.

Methods:

The electronic theatre database (Theatreman) was used

to identify all maxillofacial surgery procedures in patients over 80

years old with duration of surgery greater than 4 h between 1997

and 2016. Intensive care length of stay (LOS), hospital LOS, and

date of death if known were established using our clinical database

(iSOFT PAS) cross-referenced against care records. Median sur-

vival calculated using Kaplan–Meier.

Results:

107 patients were identified (60 male, 47 female) with a

median age of 84 years (range, 80–94 years). 94 had malignant,

and 13 locally invasive disease. All underwent local resection.

82 had neck dissections, 11 had free flaps, and 18 had local flap

reconstruction. No flaps failed. The malignant cases median oper-

ation duration was 421 min (250–1170 min) compared to local

disease cases 296 min (244–383 min). Malignant disease median

ITU LOS was 1 day, five died in hospital, four within 30 days of

surgery and one within 24 h. Their median hospital LOS was 11

days (1–132 days) and median survival 17 months. Local disease

median survival was 63 months. None required ITU, median hos-

pital LOS was 3 days (1–34), and none died in hospital or within

30 days.

Conclusion:

30 day and in hospital mortality is low and confined

to malignant disease. Long-term survival is markedly impaired in

malignant disease.

http://dx.doi.org/10.1016/j.ijom.2017.02.430

125

I brachytherapy alone for recurrent or locally advanced

salivary gland cancers of maxillary region

M.W. Huang

∗

, L. Zheng, Y. Shi, S.M. Liu, J. Zhang,

J.G. Zhang

Department of Oral and Maxillofacial Surgery, Peking

University School and Hospital of Stomatology, Beijing, China

Background:

It is still a problem to treat unresectable recurrent

or locally advanced salivary gland cancers of maxillary region,

which had a low five-year local control of 35–46%.

Objectives:

To present our treatment experiences and results, and

to evaluate the feasibility and effectiveness of

125

I brachyther-

apy in recurrent and/or locally advanced salivary gland cancers of

maxillary region.

Methods:

36 patients with recurrent and/or locally advanced sali-

vary gland cancers of maxillary region completed

125

I implant

brachytherapy in Stomatology School and Hospital of Peking Uni-

versity from 2010 to 2015. Eighteen cases were recurrent cases

after prior surgeries and radiation. And other 18 cases were pri-

mary tumours. All patients received interstitial

125

I seeds implant

alone under the three-dimensional individual template guide. The

prescribed dose was 120–160 Gy. The activity of

125

I seeds were

18.5–33.3MBq per seed. The number of seeds implanted was

16–125 (median, 55).

Findings and Conclusion:

Followed 6–65 months (median, 38

months), the two-year and five-year local control rates were

86.5% and 60.2%, respectively. The two-year and five-year over-

all survival rates were 93.8% and 66.2%. Tumours >6 cm had

significantly lower local control and survival rates. No severe

complications (Radiation Therapy Oncology Group, 3–4) were

observed during the follow-up.

125

I brachytherapy was an elec-

tive alternative to treat local advanced unresectable or recurrent

salivary gland cancers of maxillary region with few complications.

http://dx.doi.org/10.1016/j.ijom.2017.02.431

Evidence on role of chemotherapy in head neck osteosarcoma

T. Ji

∗

, Y.M. Chen, S. Gokavarapu, W. Cao

Department of Oral Maxillofacial – Head Neck Oncology, Ninth

People’s Hospital, School of Medicine, Shanghai Jiao Tong

University, Shanghai, China

Background:

Osteosarcoma is an aggressive bone malignancy

rarely presenting in head and neck sites, the trials for extrem-

ity osteosarcoma show improved survival by chemotherapy. The

head and neck osteosarcomas (HNOs) were excluded in these tri-

als because of atypical presentation and disease course. Further,

sufficient numbers were not possible for a trial.

Objectives:

We present a largest retrospective study from single

institute investigating the role of chemotherapy in the management

of HNOs.